A5022272687- Cardiac Imaging and Diagnostics
- Acute Myocardial Infarction Research
- Cardiac Ischemia and Reperfusion
- Cardiovascular Function and Risk Factors
- Cardiac Arrest and Resuscitation
- Heart Failure Treatment and Management
- Cardiac electrophysiology and arrhythmias
- Mechanical Circulatory Support Devices
- Coronary Interventions and Diagnostics
- Advanced MRI Techniques and Applications
- Cardiac Structural Anomalies and Repair
- Cardiac Valve Diseases and Treatments
- Cardiovascular Disease and Adiposity
- Cardiac Fibrosis and Remodeling
- Acute Ischemic Stroke Management
- Cardiac pacing and defibrillation studies
- Cardiovascular Effects of Exercise
- Signaling Pathways in Disease
- Atrial Fibrillation Management and Outcomes
- Atherosclerosis and Cardiovascular Diseases
- Cardiac, Anesthesia and Surgical Outcomes
- Viral Infections and Immunology Research
- Anesthesia and Neurotoxicity Research
- Blood Pressure and Hypertension Studies
- Potassium and Related Disorders
Hôpital Louis Pradel
2015-2024
Hospices Civils de Lyon
2015-2024
Laboratoire CarMeN
2015-2024
Université Claude Bernard Lyon 1
2013-2024
Inserm
2014-2024
Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
2023-2024
Délégation Régionale Auvergne-Rhône-Alpes
2024
Université Paris-Saclay
2023
Lille’s Cardiology Hospital
2008-2022
Centre National de la Recherche Scientifique
2008-2022
In patients who have chronic heart failure with reduced left ventricular ejection fraction, severe secondary mitral-valve regurgitation is associated a poor prognosis. Whether percutaneous repair improves clinical outcomes in this patient population unknown.We randomly assigned had mitral (defined as an effective regurgitant orifice area of >20 mm2 or volume >30 ml per beat), fraction between 15 and 40%, symptomatic failure, 1:1 ratio, to undergo addition receiving medical therapy...
Experimental evidence suggests that cyclosporine, which inhibits the opening of mitochondrial permeability-transition pores, attenuates lethal myocardial injury occurs at time reperfusion. In this pilot trial, we sought to determine whether administration cyclosporine percutaneous coronary intervention (PCI) would limit size infarct during acute infarction.We randomly assigned 58 patients who presented with ST-elevation infarction receive either an intravenous bolus 2.5 mg per kilogram body...
Experimental and clinical evidence suggests that cyclosporine may attenuate reperfusion injury reduce myocardial infarct size. We aimed to test whether would improve outcomes prevent adverse left ventricular remodeling.In a multicenter, double-blind, randomized trial, we assigned 970 patients with an acute anterior ST-segment elevation infarction (STEMI) who were undergoing percutaneous coronary intervention (PCI) within 12 hours after symptom onset had complete occlusion of the culprit...
Background— SCIPIO is a first-in-human, phase 1, randomized, open-label trial of autologous c-kit + cardiac stem cells (CSCs) in patients with heart failure ischemic etiology undergoing coronary artery bypass grafting (CABG). In the present study, we report surgical aspects and interim magnetic resonance (CMR) results. Methods Results— A total 33 (20 CSC-treated 13 control subjects) met final eligibility criteria were enrolled SCIPIO. CSCs isolated from right atrial appendage harvested...
Under physiological conditions, Ca(2+) transfer from the endoplasmic reticulum (ER) to mitochondria might occur at least in part contact points between 2 organelles and involves VDAC1/Grp75/IP3R1 complex. Accumulation of into mitochondrial matrix may activate chaperone cyclophilin D (CypD) trigger permeability transition pore opening, whose role ischemia/reperfusion injury is well recognized. We questioned here whether ER play a cardiomyocyte death after hypoxia-reoxygenation.We report that...
Inflammation is a key factor of myocardial damage in reperfused ST-segment-elevation infarction. We hypothesized that colchicine, potent anti-inflammatory agent, may reduce infarct size (IS) and left ventricular (LV) remodeling at the acute phase infarction.In this double-blind multicenter trial, we randomly assigned patients admitted for first episode infarction referred primary percutaneous coronary intervention to receive oral colchicine (2-mg loading dose followed by 0.5 mg twice day) or...
Secondary (or functional) mitral regurgitation (SMR) occurs frequently in chronic heart failure (HF) with reduced left ventricular (LV) ejection fraction, resulting from LV remodelling that prevents coaptation of the valve leaflets. contributes to progression symptoms and signs HF confers worse prognosis. The management patients SMR is complex requires timely referral a multidisciplinary Heart Team. Optimization pharmacological device therapy according guideline recommendations crucial....
Left ventricular (LV) function is generally assessed independent of structural remodeling and vice versa. The purpose this study was to evaluate a novel LV global index (LVGFI) that integrates structure with assess its predictive value for cardiovascular (CV) events throughout adult life in multiethnic population men women without history CV diseases at baseline. A total 5004 participants the Multi-Ethnic Study Atherosclerosis underwent cardiac magnetic resonance were followed up median 7.2...
Background— Delayed stent implantation after restoration of normal epicardial flow by a minimalist immediate mechanical intervention aims to decrease the rate distal embolization and impaired myocardial reperfusion percutaneous coronary intervention. We sought confirm whether delayed stenting (DS) approach (24–48 hours) improves reperfusion, versus stenting, in patients with acute ST-segment–elevation infarction undergoing primary Methods Results— In prospective, randomized, open-label...
The association of longitudinal changes in left ventricular (LV) structure and function with myocardial fibrosis is unclear. We relate temporal body size-indexed LV mass (LVMi) end-diastolic volume indexed to surface area, mass-to-volume ratio, ejection fraction (LVEF) from cine cardiac magnetic resonance for 10 years, replacement scar assessed late gadolinium enhancement, lower postcontrast T1 times reflecting greater diffuse measured at the end follow-up period. All participants (n=1813)...
Incidence and mortality rates for cardiovascular disease are declining, but it still remains a major cause of morbidity mortality. Drug treatments to slow the progression atherosclerosis focus on reducing cholesterol levels. The paradigm shift consider an inflammatory by itself has led development new treatments. In this article, we discuss pathophysiology inflammation attention therapeutics targeting different pathways myocardial infarction. atherosclerosis, colchicine is included in...
In the COVERT-MI randomised placebo-controlled trial, oral administration of high-dose colchicine at time reperfusion and for 5 days in acute ST-elevated myocardial infarction did not reduce infarct size but was associated with a significant increase left ventricular thrombus (LVT) comparison to placebo. We aimed assess 1-year clinical outcomes study population.
We examined whether IV administration of cyclosporine in combination with thrombolysis might reduce cerebral infarct size.Patients aged 18 to 85 years, presenting an anterior-circulation stroke and eligible for thrombolytic therapy, were enrolled this multicenter, single-blinded, controlled trial. Fifteen minutes after randomization, patients received either bolus injection 2.0 mg/kg (Sandimmune, Novartis) or placebo. The primary endpoint was volume on MRI at 30 days. Secondary endpoints...